GeneDx Holdings Corp.
WGS- Exchange
- Nasdaq
- Industry
- Services-Health Services
- SEC CIK
- 0001818331
In the last 90 days, GeneDx Holdings Corp. insiders filed 0 open-market purchases and 5 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $2.17B in total; ARK Invest is the only superinvestor holding it.
Key figures
- Market capClose on Nov 16, 2026
- $1.53B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.84M in total
- 5
- 13F holdersQ2 2026, −16 vs. previous quarter
- 226
- 13F valueReported value at the end of Q2 2026
- $2.17B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $427.5M
- +40.0% year over year
- Net income, FY2025
- -$21.0M
- No comparable prior period
- Free cash flow, FY2025
- $14.3M
- No comparable prior period
- Revenue, Q3 FY2026
- $123.1M
- +5.4% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $21.0M (4.9% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 6.55M
- Shares sold short
- Change
- +531.8K
- +8.8% vs. previous
- Days to cover
- 7.27
- At average daily volume
Superinvestors holding WGS, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding GeneDx Holdings Corp. on Form 13F. Percentages are the stock's share of each portfolio.
Latest insider trades
See all insider tradesOpen-market purchases and sales by GeneDx Holdings Corp. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 18, 2026 (view filing)4:43 PM ET | Sep 16 | 2 days | Stueland KatherineCHIEF EXECUTIVE OFFICER | SSaleClass A Common Stock | −10.5K | $97.61 | −$1.03M | −8.3%115.5K after | 5 lots |
| Sep 18, 2026 (view filing)4:39 PM ET | Sep 16 | 2 days | Feeley KevinCHIEF FINANCIAL OFFICER | SSaleClass A Common Stock | −3.73K | $97.61 | −$363.9K | −7.7%44.9K after | 5 lots |
| Sep 11, 2026 (view filing)4:13 PM ET | Sep 9 | 2 days | Stueland KatherineCHIEF EXECUTIVE OFFICER | SSaleClass A Common Stock | −3.69K | $84.22 | −$310.9K | −3.3%107.2K after | |
| Sep 11, 2026 (view filing)4:10 PM ET | Sep 9 | 2 days | Feeley KevinCHIEF FINANCIAL OFFICER | SSaleClass A Common Stock | −1.28K | $84.22 | −$108.2K | −3.0%41.5K after | |
| Sep 3, 2026 (view filing)4:09 PM ET | Sep 1 | 2 days | Feeley KevinCHIEF FINANCIAL OFFICER | SSaleClass A Common Stock | −372 | $83.84 | −$31.2K | −0.9%40.3K after | |
| Jun 18, 2026 (view filing) | Jun 16 | 2 days | Feeley KevinCHIEF FINANCIAL OFFICER | SSaleClass A Common Stock | −3.73K | $60.76 | −$226.6K | −8.5%40.0K after | 3 lots |
| Jun 18, 2026 (view filing) | Jun 16 | 2 days | Stueland KatherineCHIEF EXECUTIVE OFFICER | SSaleClass A Common Stock | −10.5K | $60.76 | −$638.1K | −9.1%104.4K after | 3 lots |
| Jun 11, 2026 (view filing) | Jun 9 | 2 days | Feeley KevinCHIEF FINANCIAL OFFICER | SSaleClass A Common Stock | −1.27K | $53.77 | −$68.1K | −3.4%36.5K after | |
| Jun 11, 2026 (view filing) | Jun 9 | 2 days | Stueland KatherineCHIEF EXECUTIVE OFFICER | SSaleClass A Common Stock | −3.64K | $53.77 | −$195.7K | −3.6%96.1K after | |
| Jun 8, 2026 (view filing)5:25 PM ET | Jun 4-5 | 4 days | Casdin Partners GP, LLC and 3 othersDirector, 10% Owner | PPurchaseClass A Common Stock, par value $0.0001 per share | +200.0K | $55.55 | +$11.1M | +5.7%3.71M after | 2 lots |
Top 10 13F holders, Q2 2026
See all 226 holdersThe largest institutional positions in GeneDx Holdings Corp. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Corvex Management LP | 4,784,570 | $328.5M | 10.21% | +1,556,421+48.2% | Added |
| Casdin Capital, LLC | 3,707,164 | $254.5M | 12.74% | +700,000+23.3% | Added |
| BlackRock, Inc. | 1,706,239 | $117.1M | 0.00% | +155,531+10.0% | Added |
| Goldman Sachs Group Inc | 1,669,441 | $114.6M | 0.01% | +334,461+25.1% | Added |
| ARK Investment Management LLCSuperinvestorARK Invest | 1,610,189 | $110.5M | 0.72% | +285,606+21.6% | Added |
| William Blair Investment Management, LLC | 1,400,653 | $96.2M | 0.29% | +625,384+80.7% | Added |
| Morgan Stanley | 988,297 | $67.8M | 0.00% | +456,062+85.7% | Added |
| Vanguard Capital Management LLC | 879,003 | $60.3M | 0.00% | +20,420+2.4% | Added |
| Citadel Advisors LLC | 865,462 | $59.4M | 0.03% | +218,061+33.7% | Added |
| First Light Asset Management, LLC | 783,923 | $53.8M | 3.27% | +540,996+222.7% | Added |
Holders of 5% or more of WGS
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of GeneDx Holdings Corp..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| CMLS Holdings LLC | 13D/A | 17.90%5.36M shares | 0.00 ppfrom 17.90% | Feb 16, 202114 filings | May 22, 2026 | SEC |
| ARK Investment Management LLCSuperinvestorARK Invest | 13G/A | 6.42%1.91M shares | +1.09 ppfrom 5.33% | Jul 9, 20213 filings | Nov 13, 2026 | SEC |
| Goldman Sachs Group Inc | 13G | 5.80%1.73M shares | +1.90 ppfrom 3.90% | Feb 9, 20245 filings | Aug 11, 2026 | SEC |
| BlackRock, Inc. | 13G | 5.50%1.62M shares | New | Jul 28, 20261 filing | Jul 28, 2026 | SEC |
| William Blair Investment Management, LLC | 13G | 5.20%1.56M shares | +0.90 ppfrom 4.30% | Jul 30, 20253 filings | Nov 6, 2026 | SEC |